Clinical Research

RSS icon
ESC Congress 2022 European Society of Cardiology

The most anticipated trials at ESC 2025

The European Society of Cardiology 2025 congress includes 10 Hot Line sessions and 28 late-breaking science sessions to showcase the latest science.

Tirzepatide, a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1), has been approved by the U.S. Food & Drug Administration (FDA) for improving glycemic control among adults with type 2 diabetes. The medication, sold by Eli Lilly and Company under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.

Tirzepatide demonstrates cardiovascular protection in head-to-head trial with dulaglutide

Tirzepatide met the primary endpoint of non-inferiority versus dulaglutide, with an 8% lower rate of MACE events included cardiovascular death, heart attack or stroke, while delivering greater reductions in A1C and weight.

PCI

Pilot study looks at same-day discharge PCI for acute coronary syndromes

Study shows same-day discharge is feasible for carefully selected, uncomplicated ACS patients. 

pharmaceutical drug approval process

New drug candidate for AFib fails in first-in-human trial—in fact, it made matters worse

Researchers had thought 2-HOBA might reduce the risk of AFib recurrence after catheter ablation procedures. What they found, however, was that treatment with the compound was actually harmful for patients instead of helpful. 

Thumbnail

Opioid overdose medications may be more effective in women, according to new PET imaging study

Experts involved in a new analysis suggest their findings could help bring about more effective treatments for opioid use disorders. 

Joshua Joseph, MD, MPH, FAHA an expert in Cardiovascular-Kidney-Metabolic (CKM) syndrome, associate professor of internal medicine, and the Endowed Professor for Research in Internal Medicine in the Division of Endocrinology, Diabetes and Metabolism at The Ohio State University Wexner Medical Center, explains the CKM advisory from the American Heart Association designed to help define and stage the disease. CKM has seen a large amount of growing interest from cardiologists in recent years.

Interest rising in CKM syndrome as connections become clearer

Cardiovascular-kidney-metabolic (CKM) syndrome is a popular research topic among cardiologists, highlighting just how closely obesity, type 2 diabetes, chronic kidney disease and cardiovascular disease are related to one another. Joshua Joseph, MD, spoke to Cardiovascular Business about this ongoing trend.

The use of intravascular lithotripsy (IVL) during percutaneous coronary intervention (PCI) is still safe and effective when patients present with calcified nodules (CNs), according to new long-term data published in EuroIntervention.[1] Researchers compared outcomes from patients with and without CNs, highlighting key similarities in stent expansion and luminal gain.

Complications after intravascular lithotripsy are rare, real-world data confirm

Shockwave Medical, now a part of Johnson & Johnson MedTech, has consistently been found safe for patients. However, many previous clinical trials excluded high-risk patients, making it important to track real-world outcomes as time goes on.

Acupuncture improves brain structure in TBI patients

MR imaging shows how acupuncture improves brain structure after TBI

New research suggests acupuncture therapy can improve white matter integrity and help reduce the symptoms associated with severe concussions.

Displaying 81 - 88 of 978
Design by Adaptive Theme